-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Reviewing MusclePharm (OTCMKTS:MSLP) and Adamis Pharmaceuticals (NASDAQ:ADMP)
Reviewing MusclePharm (OTCMKTS:MSLP) and Adamis Pharmaceuticals (NASDAQ:ADMP)
MusclePharm (OTCMKTS:MSLP – Get Rating) and Adamis Pharmaceuticals (NASDAQ:ADMP – Get Rating) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.
Insider & Institutional Ownership
15.5% of MusclePharm shares are owned by institutional investors. Comparatively, 8.6% of Adamis Pharmaceuticals shares are owned by institutional investors. 60.7% of MusclePharm shares are owned by insiders. Comparatively, 5.9% of Adamis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Get MusclePharm alerts:Earnings and Valuation
This table compares MusclePharm and Adamis Pharmaceuticals' revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
MusclePharm | $50.04 million | 0.07 | -$12.87 million | ($0.58) | -0.17 |
Adamis Pharmaceuticals | $2.21 million | 14.59 | -$45.83 million | N/A | N/A |
Profitability
This table compares MusclePharm and Adamis Pharmaceuticals' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
MusclePharm | -38.51% | N/A | -169.56% |
Adamis Pharmaceuticals | N/A | -151.88% | -96.12% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for MusclePharm and Adamis Pharmaceuticals, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
MusclePharm | 0 | 0 | 0 | 0 | N/A |
Adamis Pharmaceuticals | 0 | 1 | 0 | 0 | 2.00 |
Volatility & Risk
MusclePharm has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.
Summary
MusclePharm beats Adamis Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
About MusclePharm
(Get Rating)
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
About Adamis Pharmaceuticals
(Get Rating)
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Receive News & Ratings for MusclePharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MusclePharm and related companies with MarketBeat.com's FREE daily email newsletter.
MusclePharm (OTCMKTS:MSLP – Get Rating) and Adamis Pharmaceuticals (NASDAQ:ADMP – Get Rating) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.
穆斯克尔帕姆(场外交易代码:MSLP-GET评级)和阿达米斯制药(纳斯达克:ADMP-GET评级)都是小盘消费品公司,但哪只股票更优?我们将根据两家公司的估值、收益、风险、股息、机构所有权、分析师建议和盈利能力等方面的实力进行比较。
Insider & Institutional Ownership
内部人与机构所有权
15.5% of MusclePharm shares are owned by institutional investors. Comparatively, 8.6% of Adamis Pharmaceuticals shares are owned by institutional investors. 60.7% of MusclePharm shares are owned by insiders. Comparatively, 5.9% of Adamis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
该公司15.5%的股份由机构投资者持有。相比之下,机构投资者持有Adamis PharmPharmticals 8.6%的股份。MusclePharm 60.7%的股份由内部人士持有。相比之下,Adamis PharmPharmticals 5.9%的股份由内部人士持有。强大的机构持股表明,捐赠基金、大型基金管理公司和对冲基金相信,一只股票有望实现长期增长。
Earnings and Valuation
收益和估值
This table compares MusclePharm and Adamis Pharmaceuticals' revenue, earnings per share and valuation.
该表格比较了MusclePharm和Adamis PharmPharmticals的营收、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
MusclePharm | $50.04 million | 0.07 | -$12.87 million | ($0.58) | -0.17 |
Adamis Pharmaceuticals | $2.21 million | 14.59 | -$45.83 million | N/A | N/A |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
穆斯克尔帕姆 | 5,004万美元 | 0.07 | -1287万美元 | ($0.58) | -0.17 |
Adamis制药公司 | 221万美元 | 14.59 | -4,583万美元 | 不适用 | 不适用 |
Profitability
盈利能力
This table compares MusclePharm and Adamis Pharmaceuticals' net margins, return on equity and return on assets.
此表比较了MusclePharm和Adamis制药公司的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
MusclePharm | -38.51% | N/A | -169.56% |
Adamis Pharmaceuticals | N/A | -151.88% | -96.12% |
净利润率 | 股本回报率 | 资产回报率 | |
穆斯克尔帕姆 | -38.51% | 不适用 | -169.56% |
Adamis制药公司 | 不适用 | -151.88% | -96.12% |
Analyst Ratings
分析师评级
This is a breakdown of current ratings and recommmendations for MusclePharm and Adamis Pharmaceuticals, as provided by MarketBeat.com.
这是由MarketBeat.com提供的MusclePharm和Adamis PharmPharmticals的当前评级和推荐细目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
MusclePharm | 0 | 0 | 0 | 0 | N/A |
Adamis Pharmaceuticals | 0 | 1 | 0 | 0 | 2.00 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
穆斯克尔帕姆 | 0 | 0 | 0 | 0 | 不适用 |
Adamis制药公司 | 0 | 1 | 0 | 0 | 2.00 |
Volatility & Risk
波动性与风险
MusclePharm has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.
MusclePharm的贝塔系数为0.17,这表明其股价的波动性比标准普尔500指数低83%。相比之下,Adamis PharmPharmticals的贝塔系数为1.05,这表明其股价的波动性比标准普尔500指数高出5%。
Summary
摘要
MusclePharm beats Adamis Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
在比较两只股票的9个因素中,MusclePharm在5个方面击败了Adamis PharmPharmticals。
About MusclePharm
关于MusclePharm
(Get Rating)
(获取评级)
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
公司在美国和国际上开发、制造、营销和分销运动营养品和营养补充剂。该公司提供一系列高性能粉末、胶囊、片剂、凝胶和随时可用的零食。该公司的MusclePharm品牌产品组合包括战斗蛋白粉和战斗挤压蛋白棒;以及支链氨基酸、肌酸、谷氨酰胺、肉碱、共轭亚油酸、鱼油、多种维生素和其他产品等基本补充剂。该公司还提供FitMisse品牌的运动营养产品,这些产品主要是为女性身体制定的,以支持女性在体重管理、瘦肌肉质量、身体成分以及一般健康和健康方面的需求;以及FitMisse Energy和FitMisse Energy品牌的功能能量饮料。它向各种运动员和健身爱好者销售其产品。该公司成立于2006年,总部设在内华达州拉斯维加斯。
About Adamis Pharmaceuticals
关于Adamis制药公司
(Get Rating)
(获取评级)
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Adamis制药公司是一家专业生物制药公司,在美国开发和销售过敏、阿片类药物过量、呼吸道和炎症性疾病治疗领域的产品。该公司的候选产品包括SYMJEPI肾上腺素预填充注射器注射产品,用于紧急治疗急性过敏反应,包括过敏反应;用于治疗哮喘的干粉吸入器产品;以及用于治疗阿片类药物过量的纳洛酮注射剂。它还提供APC400,这是一种用于减少正在接受癌症治疗的患者的放射性皮炎的坦普尔凝胶;以及APC410,用于治疗呼吸道疾病,包括哮喘、呼吸道合胞病毒、流感和新冠肺炎。此外,该公司还提供皮质类固醇、激素替代疗法、医院外包产品和注射剂;以及动物兽药产品。Adamis制药公司成立于2006年,总部设在加利福尼亚州圣地亚哥。
Receive News & Ratings for MusclePharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MusclePharm and related companies with MarketBeat.com's FREE daily email newsletter.
接受MusclePharm日报的新闻和评级-在下面输入您的电子邮件地址,即可通过MarketBeat.com的免费每日电子邮件时事通讯收到对MusclePharm和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧